Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06264505
Starting soon Observational

Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study

NCT06264505 · tracked via the Priya Life Science USA tracker
Sponsor
Power Life Sciences Inc
Phase
Observational
Started
2025-03
Last updated
2024-02-28

Condition(s) studied

Soft Tissue Sarcoma

Study summary

Generally, specific demographic cohorts exhibit higher participation rates in medical research, yet there exists a scarcity of research elucidating the trial attributes impacting the engagement of these particular demographics.

The primary objective of this study is to gather extensive data on the clinical trial experiences of individuals diagnosed with soft tissue sarcoma, with the aim of identifying factors hindering patient enrollment or trial completion.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients diagnosed with soft tissue sarcoma * Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination. Exclusion Criteria: * Refusal of consent * Women of childbearing potential without a negative pregnancy test; or women who are lactating. * Any serious and/or unstable pre-existing medical disorders

Primary outcome measure(s)

  • Rate of patients in soft tissue sarcoma clinical research — 3 months
  • Number of soft tissue sarcoma study participants who maintain involvement until study finish — 12 months

Trial sites (1)

FacilityCityRegionStatus
Power Life Sciences San Francisco California

More Power Life Sciences Inc. trials in the USA

A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa Starting soon
Assessing Patient Engagement in Keratoconus Clinical Research Starting soon
Understanding Patient Engagement Trends in TBI Clinical Research Starting soon
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study Starting soon
Understanding of Participation Trends Within Generalized Anxiety Disorder Patients Involved in Clinical Trials Starting soon

Other trials for the same condition

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS Active, not recruiting
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06264505 on ClinicalTrials.gov ↗ ← All trials in the USA